[EPZM] Epizyme, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 554.46 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 11.75 Change: 0.05 (0.43%)
Ext. hours: Change: 0 (0%)

chart EPZM

Refresh chart

Strongest Trends Summary For EPZM

EPZM is in the medium-term down -17% below S&P in 1 year. In the long-term down -42% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemias with genetic alterations of the MLL gene; and a Phase I/II clinical trial of another product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT for the treatment of a genetically defined subtype of non-Hodgkin lymphoma and solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdo

Fundamental Ratios
Shares Outstanding57.22 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -90.4% Sales Growth - Q/Q-91.2% P/E
P/E To EPS Growth P/S19.17 P/BV2.54 Price/Cash Per Share
Price/Free Cash Flow-14.75 ROA-43.21% ROE-50.12% ROI
Current Ratio20.83 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin-378.54% Net Profit Margin-378.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities117.28 M Cash From Investing Activities-40.16 M Cash From Operating Activities-22.71 M Gross Profit
Net Profit-61.33 M Operating Profit-61.38 M Total Assets253.27 M Total Current Assets247.4 M
Total Current Liabilities11.88 M Total Debt1.68 M Total Liabilities34.89 M Total Revenue910 K
Technical Data
High 52 week15.12 Low 52 week5.22 Last close10.27 Last change2.6%
RSI42.98 Average true range0.54 Beta1.89 Volume427.11 K
Simple moving average 20 days-2.05% Simple moving average 50 days-13.08% Simple moving average 200 days-15.07%
Performance Data
Performance Week1.68% Performance Month-15.75% Performance Quart-18.3% Performance Half-22.43%
Performance Year9.96% Performance Year-to-date66.72% Volatility daily2.82% Volatility weekly6.31%
Volatility monthly12.93% Volatility yearly44.79% Relative Volume342.21% Average Volume648.55 K
New High New Low

News

2020-06-03 11:30:03 | Epizyme EPZM Down 4.4% Since Last Earnings Report: Can It Rebound?

2020-05-14 09:22:01 | Epizyme EPZM: Strong Industry, Solid Earnings Estimate Revisions

2020-05-13 17:12:00 | Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program

2020-05-07 10:51:02 | Allogene's ALLO Q1 Loss Widens Y/Y, Pipeline Progresses

2020-05-05 09:11:01 | Epizyme's EPZM Q1 Earnings Beat Estimates, Revenues Miss

2020-05-05 08:46:30 | Edited Transcript of EPZM earnings conference call or presentation 4-May-20 1:00pm GMT

2020-05-04 19:00:56 | Epizyme Inc EPZM Q1 2020 Earnings Call Transcript

2020-05-04 07:45:11 | Epizyme EPZM Reports Q1 Loss, Misses Revenue Estimates

2020-05-04 07:04:32 | Epizyme: Q1 Earnings Insights

2020-05-04 06:30:00 | Epizyme Reports Business Progress and First Quarter 2020 Financial Results

2020-04-27 12:32:04 | Earnings Preview: Epizyme EPZM Q1 Earnings Expected to Decline

2020-04-27 06:30:00 | Epizyme Announces Date of First Quarter 2020 Financial Results

2020-04-26 10:02:25 | Is Epizyme, Inc.'s NASDAQ:EPZM CEO Overpaid Relative To Its Peers?

2020-04-19 07:02:00 | 3 “Strong Buy” Biotech Stocks with FDA Approvals on the Horizon

2020-04-08 18:56:48 | Is Epizyme Inc EPZM A Good Stock To Buy?

2020-03-25 11:30:03 | Epizyme EPZM Down 24.9% Since Last Earnings Report: Can It Rebound?

2020-03-20 06:30:00 | Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer

2020-03-04 18:36:20 | Edited Transcript of EPZM earnings conference call or presentation 24-Feb-20 1:30pm GMT

2020-02-26 06:39:54 | Epizyme, Inc. Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

2020-02-25 12:09:02 | Analysts: 3 Healthcare Stocks to Buy on Coronavirus Weakness

2020-02-25 09:38:02 | Epizyme EPZM Q4 Earnings Miss Estimates, Revenues Beat

2020-02-25 09:28:02 | Are Options Traders Betting on a Big Move in Epizyme EPZM Stock?

2020-02-25 05:17:31 | Here are the Mass.-based firms hit hardest in Monday's stock rout

2020-02-24 07:45:12 | Epizyme EPZM Reports Q4 Loss, Tops Revenue Estimates

2020-02-24 06:30:00 | Epizyme, Inc. to Host Earnings Call

2020-02-24 06:30:00 | Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

2020-02-23 18:38:25 | The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

2020-02-20 08:42:01 | Epizyme EPZM to Report Q4 Earnings: What's in the Cards?

2020-02-19 09:21:02 | Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates

2020-02-18 06:30:00 | Epizyme Announces Date of Fourth Quarter and Full Year 2019 Results and Presentations at Upcoming Investor Conferences

2020-02-14 08:23:03 | The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering

2020-02-14 06:30:00 | Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK™ tazemetostat for the Treatment of Follicular Lymphoma

2020-02-12 06:55:00 | Investors Who Bought Epizyme NASDAQ:EPZM Shares Three Years Ago Are Now Up 81%

2020-02-06 17:50:10 | Epizyme EPZM Stock Sinks As Market Gains: What You Should Know

2020-02-05 11:52:05 | Steven Cohen Renews His Interest in Verastem

2020-01-31 17:50:10 | Epizyme EPZM Dips More Than Broader Markets: What You Should Know

2020-01-29 09:59:02 | Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data

2020-01-24 12:00:05 | Are You Looking for a Top Momentum Pick? Why Epizyme EPZM is a Great Choice

2020-01-24 10:44:57 | The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study

2020-01-24 09:57:02 | Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma

2020-01-24 05:52:07 | Epizyme's Tazemetostat Drug For Epithelioid Sarcoma Gets Accelerated FDA Approval

2020-01-23 18:07:33 | FDA approves local biotech's first rare-cancer drug

2020-01-23 17:16:00 | Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ tazemetostat for the Treatment of Patients with Epithelioid Sarcoma

2020-01-23 09:34:02 | Axsome AXSM Completes Patient Randomization in TRD Study

2020-01-23 09:04:28 | Benzinga Pro's Top 5 Stocks To Watch For Thurs., Jan. 23, 2020: CODX, LUV, INTC, PAYC, EPZM

2020-01-22 11:30:04 | Is Epizyme EPZM Outperforming Other Medical Stocks This Year?

2020-01-22 10:00:03 | Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance

2020-01-22 08:57:01 | Is the Options Market Predicting a Spike in Epizyme EPZM Stock?

2020-01-21 09:26:02 | Puma Biotech's PBYI Breast Cancer Drug Nerlynx Aids Growth

2020-01-20 14:04:15 | The Week Ahead In Biotech: Focus On Epizyme, Merck Ahead Of PDUFA Dates, J&J To Kickstart Big Pharma Earnings